Payment overview · 2025
General Payments
$149.97
6 reported records · 5 companies
Healthcare provider profile · identity verified
Jose A Vazquez, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · RIO GRANDE CITY, TX · NPI 1134147549
Verified facts
What the public records show
CMS Open Payments records show Jose A Vazquez, M.D. received $149.97 in general payments during 2025 across 6 reported records.
Boston Scientific Corporation accounted for 36.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Linzess by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $54.68 | 36.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $36.05 | 24.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.97 | 14.7% | 1 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $18.84 | 12.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.43 | 12.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $149.97 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| General - Biliary Devices Normalized: general biliary devices |
Device | Boston Scientific Corporation | $54.68 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $36.05 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.97 | 1 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $18.84 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $18.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
102 | 34 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
147 | 41 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metformin Hcl | Metformin Hcl | 482 | 123 |
| Atorvastatin Calcium | Atorvastatin Calcium | 402 | 106 |
| Jardiance | Empagliflozin | 385 | 86 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 337 | 98 |
| Amlodipine Besylate | Amlodipine Besylate | 307 | 100 |
| Pantoprazole Sodium | Pantoprazole Sodium | 257 | 78 |
| Levothyroxine Sodium | Levothyroxine Sodium | 248 | 61 |
| Losartan Potassium | Losartan Potassium | 243 | 71 |
| Gabapentin | Gabapentin | 232 | 54 |
| Januvia | Sitagliptin Phosphate | 191 | 37 |
| Donepezil Hcl | Donepezil Hcl | 185 | 28 |
| Omeprazole | Omeprazole | 165 | 39 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 162 | 57 |
| Hydralazine Hcl | Hydralazine Hcl | 161 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 160 | 41 |
| Paroxetine Hcl | Paroxetine Hcl | 157 | 41 |
| Montelukast Sodium | Montelukast Sodium | 147 | 31 |
| Ozempic | Semaglutide | 147 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 146 | 87 |
| Sertraline Hcl | Sertraline Hcl | 146 | 21 |
| Tramadol Hcl | Tramadol Hcl | 145 | 55 |
| Simvastatin | Simvastatin | 139 | 28 |
| Furosemide | Furosemide | 137 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 137 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 136 | 43 |
| Spironolactone | Spironolactone | 134 | 27 |
| Meloxicam | Meloxicam | 132 | 52 |
| Memantine Hcl | Memantine Hcl | 131 | 16 |
| Alendronate Sodium | Alendronate Sodium | 129 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 126 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 118 | 31 |
| Lisinopril | Lisinopril | 116 | 32 |
| Trazodone Hcl | Trazodone Hcl | 115 | 14 |
| Linzess | Linaclotide | 102 | 34 |
| Diclofenac Sodium | Diclofenac Sodium | 100 | 56 |
| Alprazolam | Alprazolam | 99 | 29 |
| Eliquis | Apixaban | 99 | 19 |
| Cilostazol | Cilostazol | 82 | 13 |
| Ibuprofen | Ibuprofen | 81 | 67 |
| Carvedilol | Carvedilol | 74 | 15 |
| Nifedipine Er | Nifedipine | 74 | 25 |
| Allopurinol | Allopurinol | 73 | 13 |
| Famotidine | Famotidine | 69 | 17 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 68 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 66 | 28 |
| Enalapril Maleate | Enalapril Maleate | 64 | 17 |
| Farxiga | Dapagliflozin Propanediol | 63 | 14 |
| Sucralfate | Sucralfate | 63 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 59 | 13 |
| Tradjenta | Linagliptin | 59 | suppressed |
| Olanzapine | Olanzapine | 57 | suppressed |
| Azithromycin | Azithromycin | 56 | 51 |
| Trulicity | Dulaglutide | 55 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 54 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 53 | 12 |
| Meclizine Hcl | Meclizine Hcl | 53 | 25 |
| Dutasteride | Dutasteride | 49 | suppressed |
| Potassium Chloride | Potassium Chloride | 49 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 49 | 19 |
| Clonidine Hcl | Clonidine Hcl | 45 | suppressed |
| Levetiracetam | Levetiracetam | 45 | suppressed |
| Atenolol | Atenolol | 44 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 42 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | 11 |
| Bumetanide | Bumetanide | 40 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | suppressed |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 36 | suppressed |
| Ezetimibe | Ezetimibe | 33 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 32 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Glipizide | Glipizide | 31 | suppressed |
| Carbamazepine Er | Carbamazepine | 30 | suppressed |
| Nystatin | Nystatin | 30 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | 12 |
| Pregabalin | Pregabalin | 30 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 29 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 29 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 28 | suppressed |
| Mupirocin | Mupirocin | 28 | 20 |
| Memantine Hcl Er | Memantine Hcl | 27 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 26 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 26 | 18 |
| Clonidine | Clonidine | 25 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Primidone | Primidone | 25 | suppressed |
| Brilinta | Ticagrelor | 24 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | 11 |
| Levemir Flexpen | Insulin Detemir | 24 | 11 |
| Amantadine | Amantadine Hcl | 23 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | 11 |
| Clonazepam | Clonazepam | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 17 |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 20 | suppressed |
| Livalo | Pitavastatin Calcium | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Vascepa | Icosapent Ethyl | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Repaglinide | Repaglinide | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 12 |
| Irbesartan | Irbesartan | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Novolog | Insulin Aspart | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 15 | 11 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 14 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Novolin R | Insulin Regular, Human | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Prolia | Denosumab | 13 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 13 | suppressed |
| True Comfort Alcohol Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 12 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 11 | suppressed |
| Amoxicillin | Amoxicillin | 11 | 11 |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Progesterone | Progesterone, Micronized | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $149.97 · 6 records | Boston Scientific Corporation | Cologuard Collection Kit, General - Biliary Devices, ImmunoCAP, VRAYLAR, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error